To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Solid Tumours
Interventions
DRUG

selumetinib (oral)

Volunteers will receive: 75 mg selumetinib oral dose in a fasted state (Treatment A) followed by a second 75 mg selumetinib oral dose in the fed state (Treatment B) with a washout period of at least 7 days between doses, or: 75 mg selumetinib oral dose in the fed state (Treatment B) followed by a second 75 mg selumetinib oral dose in the fasted state (Treatment A) with a washout period of at least 7 days between doses.

Trial Locations (1)

Unknown

Research Site, Overland Park

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY